[go: up one dir, main page]

WO2024226822A3 - Cd11a tage compositions and uses thereof - Google Patents

Cd11a tage compositions and uses thereof Download PDF

Info

Publication number
WO2024226822A3
WO2024226822A3 PCT/US2024/026301 US2024026301W WO2024226822A3 WO 2024226822 A3 WO2024226822 A3 WO 2024226822A3 US 2024026301 W US2024026301 W US 2024026301W WO 2024226822 A3 WO2024226822 A3 WO 2024226822A3
Authority
WO
WIPO (PCT)
Prior art keywords
tage
cd11a
compositions
guide rna
specific guide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2024/026301
Other languages
French (fr)
Other versions
WO2024226822A2 (en
Inventor
Benjamin G. GOWEN
Mary JANATPOUR
Spencer WEI
Weng IN LEONG
Kory MELTON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Spotlight Therapeutics Inc
Original Assignee
Spotlight Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Spotlight Therapeutics Inc filed Critical Spotlight Therapeutics Inc
Publication of WO2024226822A2 publication Critical patent/WO2024226822A2/en
Publication of WO2024226822A3 publication Critical patent/WO2024226822A3/en
Anticipated expiration legal-status Critical
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • C07K14/70553—Integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2845—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C12N9/222—Clustered regularly interspaced short palindromic repeats [CRISPR]-associated [CAS] enzymes
    • C12N9/226—Class 2 CAS enzyme complex, e.g. single CAS protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Provided herein are TAGE agents and DNA targeting systems comprising an anti-CD11a antigen-binding polypeptide, a site-directed modifying polypeptide and a Tumor Necrosis Factor Alpha-induced Protein 3 (TNFAIP3)-specific guide RNA or a Suppressor of Cytokine Signaling 1 (SOCS1)-specific guide RNA, and uses thereof.
PCT/US2024/026301 2023-04-26 2024-04-25 Cd11a tage compositions and uses thereof Pending WO2024226822A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363498412P 2023-04-26 2023-04-26
US63/498,412 2023-04-26

Publications (2)

Publication Number Publication Date
WO2024226822A2 WO2024226822A2 (en) 2024-10-31
WO2024226822A3 true WO2024226822A3 (en) 2025-04-03

Family

ID=93257493

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/026301 Pending WO2024226822A2 (en) 2023-04-26 2024-04-25 Cd11a tage compositions and uses thereof

Country Status (1)

Country Link
WO (1) WO2024226822A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190153476A1 (en) * 2012-12-12 2019-05-23 The Broad Institute, Inc. Crispr-cas systems for altering expression of gene products
US20220002695A1 (en) * 2019-03-22 2022-01-06 Spotlight Therapeutics Targeted active gene editing agent and methods of use

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190153476A1 (en) * 2012-12-12 2019-05-23 The Broad Institute, Inc. Crispr-cas systems for altering expression of gene products
US20220002695A1 (en) * 2019-03-22 2022-01-06 Spotlight Therapeutics Targeted active gene editing agent and methods of use

Also Published As

Publication number Publication date
WO2024226822A2 (en) 2024-10-31

Similar Documents

Publication Publication Date Title
CA2383926A1 (en) Functional genomics using zinc finger proteins
WO2021226555A3 (en) Chromatin remodelers to enhance targeted gene activation
CA3204810A1 (en) Reprogrammable tnpb polypeptides and use thereof
Du et al. Incorporation of non-canonical amino acids into antimicrobial peptides: advances, challenges, and perspectives
US20080176288A1 (en) Recombinant Production of Polyanionic Polymers, and Uses Thereof
BR112022009670A2 (en) EFFECTOR POLYPEPTIDES OF CRISPR-CAS AND METHODS OF USE THEREOF
EP4570319A3 (en) Brm targeting compounds and associated methods of use
WO2007024743A3 (en) Proteolysis resistant antibody preparations
CA2403786A1 (en) Toy vehicle crashset having rebound mechanism
AU681705B2 (en) Endosomolytically active particles
EP2298796A3 (en) Staphylococcus aureus proteins and nucleic acids
EP1088890A3 (en) Recombinant BPI proteins, uses of BPI proteins, and methods of preparing same
WO2003052057A3 (en) Egvi endoglucanase and nucleic acids encoding the same
WO2022169913A3 (en) Synthetic degrader system for targeted protein degradation
WO2022064494A3 (en) Methods and compositions for treating coronaviral infections
WO2021072129A3 (en) Proteins containing multiple, different unnatural amino acids and methods of making and using such proteins
WO2024226822A3 (en) Cd11a tage compositions and uses thereof
WO2001044809A3 (en) Evaluation of biological agents in living target cells
WO2005079523A3 (en) Novel teleost derived antimicrobal polypeptides
WO2023039534A3 (en) Compositions comprising a cas12i polypeptide and uses thereof
WO2024259295A3 (en) Reprogrammable fanzor polynucleotides and uses thereof
AU2002320301A1 (en) Novel pgc-1 isoforms and uses therefor
WO2023130022A3 (en) Cystatin rna compositions for tissue engineering
WO2024233366A3 (en) Modified cas9-iid nucleases and uses thereof
WO2024196733A3 (en) Components, compositions, and methods for control of gene editing